8/4/2022 7:37:28 AM
Karyopharm Q2 Net Loss $49.1 Mln Vs Net Loss $53.6 Mln Last Year
7/21/2022 7:28:53 AM
Karyopharm Gets Full Marketing Authorisation From EU For NEXPOVIO For Treatment Of Multiple Myeloma
7/1/2022 7:02:33 AM
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/25/2022 7:02:18 AM
The European Myeloma Network And Karyopharm Announce Dosing Of First Patient In Collaborative EMN29/XPORT-MM-031 Study
5/20/2022 10:49:50 AM
Karyopharm Receive Positive CHMP Opinion For NEXPOVIO For Treatment Of Patients With Refractory Multiple Myeloma
5/20/2022 8:47:48 AM
Karyopharm And Menarini Group Receive Positive CHMP Opinion For NEXPOVIO For Patients With Refractory Multiple Myeloma
5/12/2022 11:02:43 AM
Karyopharm Announces XPOVIO Data To Be Presented
5/5/2022 7:09:52 AM
Karyopharm Q1 Loss/shr Narrows To $0.53 From $0.77 Last Year
3/16/2022 7:04:58 AM
Karyopharm To Present Phase 3 SIENDO Study Of Selinexor In Advanced Or Recurrent Endometrial Cancer At ESMO
3/14/2022 7:10:49 AM
Karyopharm Therapeutics Appoints Elhan Webb As SVP Of Investor Relations
2/22/2022 7:18:01 AM
Karyopharm Names Patricia Judson As SVPof Medical Strategy